new drugs, we have been increasing the global R&D capabilities by establishing research centers in India, China, and the United States. In virtue of our major products including URSA, growth potential was recognized and for Daewoong’s the first time in Korean pharmaceutical industry, we were selected for the in ‘World Class 300 project’ 2012, a government supported global business development project. We were also selected as Pharmaceutical by the government in 2012, for investing more than 10% of our ‘Innovative Company’ sales into R&D. Product Portfolio ◦ Classifi- Section Use Date of No Product Name Main Ingredient Formulation cation (Bio/Synthesis) (Indications) Sales Olmesartan Hypertension 1 IMD Comb. Olostar Tablet 2014 Rosuvastatin Dyslipidemia 2 Bio-similar Bio Eposis Erythropoietin anemia Injection growth hormone 3 Bio-similar Bio Caretropin Somatropin Injection deficiency Botulinum toxin 4 Bio Bio Nabota glabellar lines Injection 2014 type A Epidermal growth diabetic foot 5 NCE Bio Easyef Spray 2001 factor ulder Ursodeoxycholic Tablet/ 6 NCE Comb. URSA Liver disease 1986 acid (UDCA) Capsule Ranitidine 7 IMD Comb. Albis Bismuth Gastroenterology Tablet 2000 Sucralfate Dioctahedral 8 IMD Comb. Smecta Diarrhea Suspension smectite prostate cancer, Branded 9 Comb. Luphere Leuprolide acetate endometriosis, Injection 2005 Generic breast cancer R&D Pipeline ◦ Classifi- Section Name of Main Ingredient Use Stage of No cation (Bio/Synthesis) Technology (Description) (Indications) Development CV Fixed-dose Hyperlipidemia/ 1 IMD Small Molecule Chemical Approved Combination Hypertension Recombinant 2 Bio-similar Bio human Bio Anemia of CRF Marketed erythropoietin α Recombinant 3 Bio-similar Bio human growth Bio Deficiency of HGH Marketed hormone Epidermal Growth 4 New Drug Biologics EGF Diabetic Foot Ulcer Marketed Factor Bio Alveolar Bone 5 Others BMP-2 Bone Formation Approved convergence Regeneration
new drugs, we have been increasing the global R&D capabilities by establishing research centers in India, China, and the United States. In virtue of our major products including URSA, Daewoong’s growth potential was recognized and for the first time in Korean pharmaceutical industry, we were selected for the ‘World Class 300 project’ in 2012, a government supported global business development project. We were also selected as ‘Innovative Pharmaceutical Company’ by the government in 2012, for investing more than 10% of our sales into R&D. ◦ Product Portfolio No Classifi- cation Section (Bio/Synthesis) Product Name Main Ingredient Use (Indications) Formulation Date of Sales 1 IMD Comb. Olostar Olmesartan Rosuvastatin Hypertension Dyslipidemia Tablet 2014 2 Bio-similar Bio Eposis Erythropoietin anemia Injection 3 Bio-similar Bio Caretropin Somatropin growth hormone deficiency Injection 4 Bio Bio Nabota Botulinum toxin type A glabellar lines Injection 2014 5 NCE Bio Easyef Epidermal growth factor diabetic foot ulder Spray 2001 6 NCE Comb. URSA Ursodeoxycholic acid (UDCA) Liver disease Tablet/ Capsule 1986 7 IMD Comb. Albis Ranitidine Bismuth Sucralfate Gastroenterology Tablet 2000 8 IMD Comb. Smecta Dioctahedral smectite Diarrhea Suspension 9 Branded Generic Comb. Luphere Leuprolide acetate prostate cancer, endometriosis, breast cancer Injection 2005 ◦ R&D Pipeline No Classifi- cation Section (Bio/Synthesis) Name of Technology Main Ingredient (Description) Use (Indications) Stage of Development 1 IMD Small Molecule CV Fixed-dose Combination Chemical Hyperlipidemia/ Hypertension Approved 2 Bio-similar Bio Recombinant human erythropoietin α Bio Anemia of CRF Marketed 3 Bio-similar Bio Recombinant human growth hormone Bio Deficiency of HGH Marketed 4 New Drug Biologics Epidermal Growth Factor EGF Diabetic Foot Ulcer Marketed 5 Bio convergence Others Alveolar Bone Regeneration BMP-2 Bone Formation Approved